This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
James Bartels, MD, and colleagues from the University of Rochester (NY) presented their work on the different therapies for supraglottic carcinoma at the Eastern Section Meeting of the Triological Society. This was a retrospective study of 1104 patients with squamous cell carcinoma of the supraglottis treated from 1970 to 1982. In general, the patients with T1 and T2 lesions were treated with surgery or radiation therapy. Patients with T3 and T4 lesions, who comprised most of the study group, were generally treated with surgery and radiation therapy. In the T2 group, 44% of the patients survived for three years with primary radiation therapy and subsequent salvage surgery, whereas 77% survived for three years with surgery combined with planned radiation therapy. In patients with T2, NO or T2, N1 lesions, there was a 64% recurrence rate with radiation therapy and a 35% recurrence rate with surgery. The patients whose lesions recurred
MYERS EN. Therapies for Supraglottic Carcinoma. Arch Otolaryngol Head Neck Surg. 1987;113(5):475. doi:10.1001/archotol.1987.01860050021007